Gene: ERBB3

2065
ErbB-3|HER3|LCCS2|MDA-BF-1|c-erbB-3|c-erbB3|erbB3-S|p180-ErbB3|p45-sErbB3|p85-sErbB3
erb-b2 receptor tyrosine kinase 3
protein-coding
12q13.2
Ensembl:ENSG00000065361 MIM:190151 Vega:OTTHUMG00000170140 UniprotKB:P21860
NG_011529.1
PubMed
0   ANCO-SNPs
ND
7   
NA (AD)  NA (ND)   (Frontal_Cortex)
2.170e-1 (AD)  4.328e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
FA2H0.948
PLEKHH10.945
MYRF0.933
ENPP20.927
COL4A50.923
MOG0.922
SLC45A30.922
TMEM1440.919
TF0.918
UGT80.917

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
PAX2-0.348
CALB2-0.347
CHRNA2-0.341
NEUROD1-0.341
SHISA8-0.336
CUX2-0.335
GOLGA6L1-0.334
PRTN3-0.328
WTIP-0.323
NPBWR1-0.323

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C5696701-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one"1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one results in increased expression of ERBB3 mRNA"23136191
C0319031-UFT protocolERBB3 protein results in increased susceptibility to 1-UFT protocol16734730
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in increased expression of ERBB3 mRNA"23136191
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in increased phosphorylation of ERBB3 protein"19509167
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"ERBB3 affects the reaction [NRG1 results in decreased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine]"19509167
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"[N-acetylglucosaminono-1,5-lactone O-(phenylcarbamoyl)oxime results in increased phosphorylation of ERBB3 protein] which results in decreased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"23029544
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"NRG1 protein promotes the reaction [2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine results in increased phosphorylation of ERBB3 protein]"19509167
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in increased expression of ERBB3 mRNA"20453058
C5486512-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester2-(1'H-indolo-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in increased expression of ERBB3 mRNA19933214
C0549192,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene"[Dichlorodiphenyldichloroethane co-treated with Dichlorodiphenyl Dichloroethylene co-treated with 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene co-treated with Aldrin co-treated with Dieldrin] results in increased expression of ERBB3 mRNA"19422813
C0859112-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [beta-hexachlorocyclohexane promotes the reaction [ERBB2 protein binds to ERBB3 protein]]12439862
C1079462,7-dihydroxynaphthalene"2,7-dihydroxynaphthalene results in decreased expression of ERBB3 mRNA"28940058
C0237042-acetamidoethanethiol2-acetamidoethanethiol analog results in decreased phosphorylation of ERBB3 protein20058253
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA"27188386
C1078756-(methylamino)pyrido(3,4-d)pyrimidine"6-(methylamino)pyrido(3,4-d)pyrimidine results in decreased activity of ERBB3 protein"15572027
D000082AcetaminophenAcetaminophen results in decreased expression of ERBB3 mRNA21420995
D000082AcetaminophenAcetaminophen results in increased expression of ERBB3 mRNA17585979
D000082Acetaminophen[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB3 mRNA25607892
C016601afimoxifeneafimoxifene inhibits the reaction [beta-hexachlorocyclohexane promotes the reaction [ERBB2 protein binds to ERBB3 protein]]12439862
D016604Aflatoxin B1Aflatoxin B1 affects the expression of ERBB3 protein20106945
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of ERBB3 mRNA27153756
D000393Air PollutantsAir Pollutants analog results in decreased expression of ERBB3 mRNA21757418
D000452Aldrin"[Dichlorodiphenyldichloroethane co-treated with Dichlorodiphenyl Dichloroethylene co-treated with 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene co-treated with Aldrin co-treated with Dieldrin] results in increased expression of ERBB3 mRNA"19422813
D000535Aluminum[APP protein modified form binds to Aluminum] which results in decreased expression of ERBB3 mRNA21298039
D000726Androgen Antagonists[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB3 mRNA25607892
D000728AndrogensAndrogens affects the localization of ERBB3 protein17634423
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of ERBB3 mRNA24449571
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of ERBB3 mRNA20106945
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of ERBB3 mRNA19770486
C072553benzyloxycarbonylleucyl-leucyl-leucine aldehydebenzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfide results in decreased expression of ERBB3 protein]20332299
C072553benzyloxycarbonylleucyl-leucyl-leucine aldehydebenzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfone results in decreased expression of ERBB3 protein]20332299
C072553benzyloxycarbonylleucyl-leucyl-leucine aldehydebenzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased expression of ERBB3 protein20332299
D004958EstradiolEGF protein promotes the reaction [Estradiol results in decreased expression of ERBB3 mRNA]24758408
D004958EstradiolEstradiol affects the expression of ERBB3 mRNA14699072
D004958EstradiolEstradiol results in decreased expression of ERBB3 mRNA20106945|2475840
D004958Estradiol[ERBB2 protein co-treated with ERBB3 protein] results in increased susceptibility to Estradiol19861407
D004958EstradiolEstradiol results in increased expression of ERBB3 mRNA15289156
C023888beta-hexachlorocyclohexane2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [beta-hexachlorocyclohexane promotes the reaction [ERBB2 protein binds to ERBB3 protein]]12439862
C023888beta-hexachlorocyclohexaneafimoxifene inhibits the reaction [beta-hexachlorocyclohexane promotes the reaction [ERBB2 protein binds to ERBB3 protein]]12439862
C023888beta-hexachlorocyclohexanebeta-hexachlorocyclohexane promotes the reaction [ERBB2 protein binds to ERBB3 protein]12439862
C006780bisphenol Abisphenol A results in decreased expression of ERBB3 mRNA16029874
C006780bisphenol Abisphenol A results in increased expression of ERBB3 mRNA22576693
C006780bisphenol Abisphenol A results in increased phosphorylation of ERBB3 protein21988766
C006780bisphenol A[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB3 mRNA25607892
C006780bisphenol A[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of ERBB3 mRNA25607892
C006780bisphenol Abisphenol A results in decreased expression of ERBB3 mRNA25181051
C006780bisphenol Abisphenol A results in increased expression of ERBB3 protein19590682
C038091butylparaben[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB3 mRNA25607892
C038091butylparaben[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of ERBB3 mRNA25607892
C018475butyraldehydebutyraldehyde results in decreased expression of ERBB3 mRNA26079696
D019256Cadmium Chloride[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of ERBB3 mRNA12634122
D000069287CapecitabineERBB3 protein results in increased susceptibility to Capecitabine16734730
D002220CarbamazepineCarbamazepine affects the expression of ERBB3 mRNA25979313
C054133casticincasticin results in increased expression of ERBB3 mRNA27862857
D002738ChloroquineChloroquine results in decreased expression of ERBB3 protein20332299
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression of ERBB3 mRNA20938992
C023600chromic oxide[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of ERBB3 mRNA12634122
C074702chromium hexavalent ionchromium hexavalent ion affects the expression of ERBB3 mRNA18053681
C017133chromous chloride[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of ERBB3 mRNA12634122
C034456CMF regimenERBB3 protein affects the susceptibility to [Epirubicin co-treated with CMF regimen]18768436
D003300Copper[NSC 689534 binds to Copper] which results in decreased expression of ERBB3 mRNA20971185
D019327Copper SulfateCopper Sulfate results in decreased expression of ERBB3 mRNA19549813
D003375CoumestrolCoumestrol results in decreased expression of ERBB3 mRNA19167446
D003471CuprizoneCuprizone results in decreased expression of ERBB3 mRNA27523638
D003471CuprizoneCuprizone results in increased expression of ERBB3 mRNA26577399
D003474CurcuminCurcumin analog results in decreased expression of ERBB3 mRNA26409325
D003474CurcuminCurcumin promotes the reaction [Folfox protocol results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of ERBB3 protein]17918158
D003474CurcuminCurcumin results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of ERBB3 protein17918158
D003474CurcuminCurcumin results in decreased expression of ERBB3 mRNA15713895
D003474CurcuminFluorouracil promotes the reaction [Curcumin results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of ERBB3 protein]17918158
D003513CycloheximideCycloheximide results in decreased expression of ERBB3 mRNA15228094
D016572CyclosporineCyclosporine results in decreased expression of ERBB3 mRNA20106945|2556210
D003630DaunorubicinDaunorubicin results in decreased expression of ERBB3 mRNA26537877|2894005
D003907DexamethasoneDexamethasone results in increased expression of ERBB3 mRNA21041162
D003976DiazinonDiazinon affects the expression of ERBB3 mRNA22546817
D003993Dibutyl Phthalate[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB3 mRNA25607892
D003993Dibutyl PhthalateDibutyl Phthalate results in increased expression of ERBB3 mRNA21266533
D003632Dichlorodiphenyldichloroethane"[Dichlorodiphenyldichloroethane co-treated with Dichlorodiphenyl Dichloroethylene co-treated with 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene co-treated with Aldrin co-treated with Dieldrin] results in increased expression of ERBB3 mRNA"19422813
D003633Dichlorodiphenyl Dichloroethylene"[Dichlorodiphenyldichloroethane co-treated with Dichlorodiphenyl Dichloroethylene co-treated with 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene co-treated with Aldrin co-treated with Dieldrin] results in increased expression of ERBB3 mRNA"19422813
D003633Dichlorodiphenyl Dichloroethylene[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB3 mRNA25607892
C036042dicyclohexyl phthalatedicyclohexyl phthalate affects the expression of ERBB3 mRNA26924002
D004026Dieldrin"[Dichlorodiphenyldichloroethane co-treated with Dichlorodiphenyl Dichloroethylene co-treated with 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene co-treated with Aldrin co-treated with Dieldrin] results in increased expression of ERBB3 mRNA"19422813
D004051Diethylhexyl Phthalate[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB3 mRNA25607892
D004054DiethylstilbestrolDiethylstilbestrol results in increased expression of ERBB3 mRNA15289156
D002117CalcitriolCalcitriol results in increased expression of ERBB3 mRNA26485663
C024629dimethyl phthalatedimethyl phthalate affects the expression of ERBB3 mRNA26924002
C025034doxifluridineERBB3 protein results in increased susceptibility to doxifluridine16734730
D004317DoxorubicinDoxorubicin results in decreased expression of ERBB3 mRNA26537877|2894005
D004317DoxorubicinERBB3 protein affects the susceptibility to Doxorubicin16217747
D004317DoxorubicinERBB3 protein inhibits the reaction [Doxorubicin results in decreased phosphorylation of AKT1 protein]16168102
C118739entinostatentinostat results in increased expression of ERBB3 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA"27188386
C038939enzacamene[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB3 mRNA25607892
C038939enzacamene[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of ERBB3 mRNA25607892
D015251EpirubicinERBB3 protein affects the susceptibility to [Epirubicin co-treated with CMF regimen]18768436
C109476epoxiconazole[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB3 mRNA25607892
D000069347Erlotinib HydrochlorideERBB3 mRNA results in decreased susceptibility to Erlotinib Hydrochloride23125191
D004997Ethinyl EstradiolEthinyl Estradiol affects the expression of ERBB3 mRNA17555576
D005047EtoposideERBB3 protein affects the susceptibility to Etoposide16217747
D005047EtoposideEtoposide results in decreased expression of ERBB3 mRNA15228094
D015025ZearalenoneZearalenone results in decreased expression of ERBB3 mRNA19371625
D005472FluorouracilFluorouracil promotes the reaction [Curcumin results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of ERBB3 protein]17918158
D005472FluorouracilFluorouracil results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of ERBB3 protein17918158
D005485FlutamideFlutamide results in decreased expression of ERBB3 mRNA24136188
C410216Folfox protocolCurcumin promotes the reaction [Folfox protocol results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of ERBB3 protein]17918158
C410216Folfox protocolFolfox protocol results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of ERBB3 protein17918158
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression of ERBB3 mRNA20938992
D019833GenisteinGenistein results in increased expression of ERBB3 mRNA15289156
D005947Glucose[NRG1 protein binds to ERBB3 protein] which results in increased transport of Glucose14711829
D017313FenretinideFenretinide results in increased expression of ERBB3 mRNA28973697
C544151jinfukangjinfukang results in increased expression of ERBB3 mRNA27392435
D007657Ketone BodiesKetone Bodies results in decreased expression of ERBB3 mRNA15469884
C490728lapatiniblapatinib results in decreased activity of ERBB3 protein19509167
C490728lapatiniblapatinib results in decreased expression of ERBB3 protein modified form19435893
C490728lapatiniblapatinib results in decreased phosphorylation of ERBB3 protein19509167
C008261lead acetate[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of ERBB3 mRNA12634122
D008044Linuron[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB3 mRNA25607892
D018021Lithium ChlorideLithium Chloride results in increased expression of ERBB3 mRNA23527032
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression of ERBB3 mRNA20938992
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of ERBB3 mRNA23103053
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of ERBB3 mRNA"26251327
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased methylation of ERBB3 promoter"26251327
D015735MifepristoneMifepristone results in decreased expression of ERBB3 mRNA19439560
D016685MitomycinERBB3 protein affects the susceptibility to Mitomycin16217747
D008942MitoxantroneMitoxantrone results in decreased expression of ERBB3 mRNA26537877|2894005
C517284monomethyl phthalatemonomethyl phthalate affects the expression of ERBB3 mRNA26924002
C523799MRK 003ERBB3 results in decreased susceptibility to MRK 00319903844
C583365N-(2-(1,1'-bicyclopropyl)-2-ylphenyl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide"N-(2-(1,1'-bicyclopropyl)-2-ylphenyl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide results in decreased expression of ERBB3 mRNA"29244179
C068836N-acetylglucosaminono-1,5-lactone O-(phenylcarbamoyl)oxime"N-acetylglucosaminono-1,5-lactone O-(phenylcarbamoyl)oxime results in increased phosphorylation of ERBB3 protein"23029544
C068836N-acetylglucosaminono-1,5-lactone O-(phenylcarbamoyl)oxime"[N-acetylglucosaminono-1,5-lactone O-(phenylcarbamoyl)oxime results in increased phosphorylation of ERBB3 protein] which results in decreased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"23029544
C022838nickel chloridenickel chloride affects the expression of ERBB3 mRNA22546817
C029938nickel sulfatenickel sulfate results in decreased expression of ERBB3 mRNA18651567
C558013NSC 689534[NSC 689534 binds to Copper] which results in decreased expression of ERBB3 mRNA20971185
C516714NVP-TAE684[EGF protein results in increased phosphorylation of and results in increased activity of ERBB3 protein] which results in decreased susceptibility to NVP-TAE68422843788
C118580octylmethoxycinnamate[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of ERBB3 mRNA25607892
C118580octylmethoxycinnamate[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of ERBB3 mRNA25607892
D017239PaclitaxelERBB3 protein results in decreased susceptibility to Paclitaxel16734730
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA"27188386
C496932panobinostatpanobinostat results in increased expression of ERBB3 mRNA26272509
D010269ParaquatParaquat results in decreased expression of ERBB3 mRNA16797015
C023036perfluorooctanoic acidperfluorooctanoic acid results in decreased expression of ERBB3 protein26879310
D010575PesticidesPesticides results in increased methylation of ERBB3 gene28396702
C006253pirinixic acidpirinixic acid results in decreased expression of ERBB3 mRNA18445702
C045362prochloraz[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB3 mRNA25607892
C035988procymidone[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB3 mRNA25607892
D011374ProgesteroneProgesterone results in increased expression of ERBB3 mRNA23012394
D011374ProgesteroneProgesterone results in increased expression of ERBB3 mRNA19690047
D011441PropylthiouracilPropylthiouracil results in decreased expression of ERBB3 mRNA24780913
D011794QuercetinQuercetin inhibits the reaction [EGF protein results in increased phosphorylation of ERBB3 protein]12888923
D011794QuercetinQuercetin inhibits the reaction [TGFA protein results in increased phosphorylation of ERBB3 protein]12888923
D011794QuercetinQuercetin results in decreased expression of and results in decreased phosphorylation of ERBB3 protein12888923
D011794QuercetinQuercetin results in decreased expression of ERBB3 mRNA21632981
D011794QuercetinQuercetin results in decreased expression of ERBB3 protein15741050
D020849Raloxifene HydrochlorideRaloxifene Hydrochloride affects the expression of ERBB3 mRNA14699072
C059514resveratrolresveratrol results in decreased expression of ERBB3 mRNA19371625
C541923sandostatinLARsandostatinLAR results in increased expression of ERBB3 mRNA17210224
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of ERBB3 mRNA25895662
D012834SilverSilver results in decreased expression of ERBB3 mRNA26014281|2655175
D012906SmokeSmoke results in decreased expression of ERBB3 mRNA21095227
C017947sodium arsenite[sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of ERBB3 mRNA12634122
C017947sodium arsenitesodium arsenite results in decreased expression of ERBB3 mRNA25879800
C017947sodium arsenitesodium arsenite results in increased expression of ERBB3 mRNA11241755
C025462sulindac sulfidebenzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfide results in decreased expression of ERBB3 protein]20332299
C025462sulindac sulfidesulindac sulfide results in decreased expression of ERBB3 protein20332299
C025463sulindac sulfonebenzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [sulindac sulfone results in decreased expression of ERBB3 protein]20332299
C025463sulindac sulfonesulindac sulfone results in decreased expression of ERBB3 protein20332299
D013629TamoxifenERBB3 protein results in decreased susceptibility to Tamoxifen16000581
D013629TamoxifenTamoxifen affects the expression of ERBB3 mRNA17555576
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of ERBB3 mRNA11162886|1968428
D013749Tetrachlorodibenzodioxin[Tetrachlorodibenzodioxin co-treated with TIPARP gene mutant form] results in increased expression of ERBB3 mRNA25975270
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin promotes the reaction [AHR protein binds to ERBB3 gene]21762485
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin promotes the reaction [AHR protein binds to ERBB3 promoter]21889950
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of ERBB3 mRNA18796159|1968428
D013750TetrachloroethyleneTetrachloroethylene results in increased expression of ERBB3 mRNA28973375
D019772TopotecanERBB3 protein affects the susceptibility to Topotecan16217747
D014118Toxins, Biological"Toxins, Biological affects the expression of ERBB3 mRNA"19682533
D014241TrichloroethylenePPARA protein inhibits the reaction [Trichloroethylene results in decreased expression of ERBB3 mRNA]15363585
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA"27188386
C012589trichostatin Atrichostatin A affects the expression of ERBB3 mRNA28542535
C012589trichostatin Atrichostatin A results in increased expression of ERBB3 mRNA24935251|2627250
C000608764triphenyl(phenylethynyl)phosphoniumtriphenyl(phenylethynyl)phosphonium results in decreased expression of ERBB3 protein26984758
C057693troglitazonetroglitazone results in decreased expression of ERBB3 mRNA28973697
D014415TunicamycinTunicamycin results in decreased expression of ERBB3 mRNA17127020
D014501UraniumUranium affects the expression of ERBB3 mRNA15672453
C005460uranyl acetateuranyl acetate affects the expression of ERBB3 mRNA15672453
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of ERBB3 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of ERBB3 mRNA28001369|2915479
D014635Valproic AcidValproic Acid results in increased expression of ERBB3 mRNA19101580|2317975
D014635Valproic AcidValproic Acid results in increased expression of ERBB3 mRNA24896083
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of ERBB3 gene25560391
C025643vinclozolin[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of ERBB3 mRNA25607892
D024483Vitamin K 3Vitamin K 3 affects the expression of ERBB3 mRNA20044591
C111237vorinostat"[NOG protein co-treated with vorinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERBB3 mRNA"27188386
C111237vorinostatvorinostat results in increased expression of ERBB3 mRNA26272509

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004709MAP kinase kinase kinase activity-IBA21873635  
GO:0004713protein tyrosine kinase activity-IBA21873635  
GO:0004713protein tyrosine kinase activityNOTIDA7556068  
GO:0004713protein tyrosine kinase activity-TAS-  
GO:0004714transmembrane receptor protein tyrosine kinase activity-IBA21873635  
GO:0004888transmembrane signaling receptor activity-IBA21873635  
GO:0004888transmembrane signaling receptor activity-ISS7514177  
GO:0005088Ras guanyl-nucleotide exchange factor activity-TAS-  
GO:0005515protein binding-IPI7592681  9516479  10572067  16273093  16729043  16832058  
16843263  17148612  17426253  19411071  20007781  20227043  
21075308  21203579  21278786  22439932  22733765  22806884  
22939624  23436906  23680147  23688700  23866081  24189400  
24557338  24658140  25241761  25326665  
GO:0005524ATP binding-IEA-  
GO:0019838growth factor binding-IPI11389077  
GO:0019838growth factor binding-ISS7514177  
GO:0030296protein tyrosine kinase activator activity-IDA7556068  
GO:0031434mitogen-activated protein kinase kinase binding-IBA21873635  
GO:0031625ubiquitin protein ligase binding-IPI27353365  
GO:0038131neuregulin receptor activity-IBA21873635  
GO:0038132neuregulin binding-IBA21873635  
GO:0038132neuregulin binding-IDA20682778  
GO:0042802identical protein binding-IPI21575594  23436906  
GO:0042803protein homodimerization activity-NAS11389077  
GO:0046934phosphatidylinositol-4,5-bisphosphate 3-kinase activity-TAS-  
GO:0046982protein heterodimerization activity-IDA10572067  
GO:0046982protein heterodimerization activity-IPI7556068  
GO ID GO Term Qualifier Evidence PubMed
GO:0000165MAPK cascade-TAS-  
GO:0003197endocardial cushion development-IEA-  
GO:0007162negative regulation of cell adhesion-IDA7556068  
GO:0007165signal transduction-IDA10572067  
GO:0007169transmembrane receptor protein tyrosine kinase signaling pathway-ISS7514177  
GO:0007275multicellular organism development-IBA21873635  
GO:0007422peripheral nervous system development-ISS-  
GO:0007507heart development-ISS-  
GO:0009968negative regulation of signal transduction-IBA21873635  
GO:0009968negative regulation of signal transduction-IDA11389077  
GO:0010628positive regulation of gene expression-IEA-  
GO:0014037Schwann cell differentiation-ISS-  
GO:0014065phosphatidylinositol 3-kinase signaling-IDA7556068  
GO:0014068positive regulation of phosphatidylinositol 3-kinase signaling-TAS17701904  
GO:0018108peptidyl-tyrosine phosphorylation-IEA-  
GO:0021545cranial nerve development-ISS-  
GO:0030154cell differentiation-IBA21873635  
GO:0033674positive regulation of kinase activity-IBA21873635  
GO:0038128ERBB2 signaling pathway-TAS-  
GO:0042060wound healing-NAS12646923  
GO:0042127regulation of cell proliferation-IDA11389077  
GO:0043066negative regulation of apoptotic process-IBA21873635  
GO:0043410positive regulation of MAPK cascade-IBA21873635  
GO:0043524negative regulation of neuron apoptotic process-ISS-  
GO:0046854phosphatidylinositol phosphorylation-IEA-  
GO:0051048negative regulation of secretion-IDA10559227  
GO:0051402neuron apoptotic process-IMP17701904  
GO:0051897positive regulation of protein kinase B signaling-TAS-  
GO:0055025positive regulation of cardiac muscle tissue development-IEA-  
GO:0061098positive regulation of protein tyrosine kinase activity-IMP7556068  
GO:0070374positive regulation of ERK1 and ERK2 cascade-IBA21873635  
GO:0070886positive regulation of calcineurin-NFAT signaling cascade-IEA-  
GO:0097192extrinsic apoptotic signaling pathway in absence of ligand-IMP17701904  
GO:2000145regulation of cell motility-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005615extracellular space-IDA11389077  
GO:0005622intracellular-IEA-  
GO:0005737cytoplasm-IBA21873635  
GO:0005886plasma membrane-TAS17701904  
GO:0005887integral component of plasma membrane-IBA21873635  
GO:0005887integral component of plasma membrane-TAS2687875  
GO:0009925basal plasma membrane-IBA21873635  
GO:0016323basolateral plasma membrane-IDA12646923  
GO:0016324apical plasma membrane-IEA-  
GO:0016328lateral plasma membrane-IEA-  
GO:0043235receptor complex-IBA21873635  
GO:0043235receptor complex-IDA23382219  
GO:0043235receptor complex-ISS7514177  
KEGG ID KEGG Term
hsa04012ErbB signaling pathway
hsa04020Calcium signaling pathway
hsa04144Endocytosis
Reactome ID Reactome Term Evidence
R-HSA-1227986Signaling by ERBB2TAS
R-HSA-1227986Signaling by ERBB2IEA
R-HSA-1236394Signaling by ERBB4TAS
R-HSA-1250196SHC1 events in ERBB2 signalingIEA
R-HSA-1250196SHC1 events in ERBB2 signalingTAS
R-HSA-1257604PIP3 activates AKT signalingTAS
R-HSA-1306955GRB7 events in ERBB2 signalingTAS
R-HSA-1358803Downregulation of ERBB2:ERBB3 signalingTAS
R-HSA-162582Signal TransductionTAS
R-HSA-162582Signal TransductionIEA
R-HSA-1643685DiseaseTAS
R-HSA-1963642PI3K events in ERBB2 signalingTAS
R-HSA-199418Negative regulation of the PI3K/AKT networkTAS
R-HSA-2219528PI3K/AKT Signaling in CancerTAS
R-HSA-2219530Constitutive Signaling by Aberrant PI3K in CancerTAS
R-HSA-5663202Diseases of signal transductionTAS
R-HSA-5673001RAF/MAP kinase cascadeTAS
R-HSA-5683057MAPK family signaling cascadesTAS
R-HSA-5684996MAPK1/MAPK3 signalingTAS
R-HSA-6785631ERBB2 Regulates Cell MotilityTAS
R-HSA-6811558PI5P, PP2A and IER3 Regulate PI3K/AKT SignalingTAS
R-HSA-8847993ERBB2 Activates PTK6 SignalingTAS
R-HSA-8848021Signaling by PTK6TAS
R-HSA-8863795Downregulation of ERBB2 signalingTAS
R-HSA-9006925Intracellular signaling by second messengersTAS
R-HSA-9006927Signaling by Non-Receptor Tyrosine KinasesTAS
R-HSA-9006934Signaling by Receptor Tyrosine KinasesTAS
R-HSA-9006934Signaling by Receptor Tyrosine KinasesIEA

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
20604875ErbB receptors and fatty acid synthase expression in aggressive head and neck squamous cell carcinomas. (2010 Nov)Silva SDOral Dis
28294470Exome sequencing deciphers a germline MET mutation in familial epidermal growth factor receptor-mutant lung cancer. (2017 Jun)Tode NCancer Sci
17409975Establishment and expression profiling of new lung cancer cell lines from Chinese smokers and lifetime never-smokers. (2006 Nov)Lam DCJ Thorac Oncol
15563701Expression of ErbB receptors and mucins in the airways of long term current smokers. (2004 Dec)O'Donnell RAThorax
17908459Expressions of tumor necrosis factor-converting enzyme and ErbB3 in rats with chronic obstructive pulmonary disease. (2007 Sep 5)Ju CRChin Med J (Engl)
29452776Women-specific risk factors for heart failure: A genetic approach. (2018 Mar)van der Kemp JMaturitas
19690148Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice. (2009 Sep 1)Ohashi KCancer Res